Results 171 to 180 of about 121,016 (287)

Chimeric Antibody Engineering Against Bacillus anthracis Lethal Toxin: Neutralization Efficacy and Mechanism of Action. [PDF]

Toxins (Basel)
Kalmantaeva OV, Marin MA, Ershova AA, Ryabko AK, Romanenko YO, Kombarova TI, Dyatlov IA, Firstova VV.   +7 more
europepmc   +1 more source

A Spatiotemporally Controlled Nanoplatform for Photothermal BRD4 Degradation Enables Synergistic Cancer Immunotherapy

Advanced Science, EarlyView.
A GSH‐responsive MOF nanoplatform acts as a Photothermolysis‐Targeting Conjugate (PTTAC). Through sophisticated step‐wise nuclear delivery, it enables NIR‐II light‐triggered photothermal degradation of BRD4. This precise strategy induces robust immunogenic cell death (ICD) and powerfully synergizes with anti‐PD‐L1 blockade to elicit a potent systemic ...
Luyi Wang, Jiasha Wu, Rui Ji, Sufeng Qiang, Yulin Shen, Yan Zuo, Shiqin Jian, Siyao Liu, Fusheng Xu, Honggang Hu, Xiaochun Hu   +10 more
wiley   +1 more source

The TCR and LCK: foundations for T-cell activation and therapeutic innovation. [PDF]

Front Immunol
Woessner NM, Uleri V, Stepanek O, Minguet S.   +3 more
europepmc   +1 more source

Programming Next‐Generation Synthetic Biosensors by Genetic Circuit Design

Advanced Science, EarlyView.
Synthetic biology enables genetic circuit‐based biosensing to detect diverse targets, process signals, and transduce them into readable outputs or intracellular regulatory activities. However, field deployment and real‐world application of such synthetic biosensors face considerable challenges in sensitivity, specificity, speed, stability, and ...
Yuanli Gao, Cheng Huang, Jiaxuan Deng, Lei Wang, Baojun Wang   +4 more
wiley   +1 more source

Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. [PDF]

World J Clin Oncol
Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F.   +4 more
europepmc   +1 more source

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong, Emily B. Tomasulo, Stefan K. Barta   +2 more
wiley   +1 more source

Special issue: advances in immunology and its applications. [PDF]

Acta Biochim Biophys Sin (Shanghai)
Han M, Wang H.
europepmc   +1 more source

Mannose‐Modified Cationic Liposome‐Based mRNA Therapeutics for Improved Triple‐Negative Breast Cancer Immunotherapy

Advanced NanoBiomed Research, EarlyView.
Schematic illustration of mTEM8‐loaded cationic liposome (cLipo‐Man/mTEM8) therapeutics for improved triple‐negative breast cancer immunotherapy. Despite triple‐negative breast cancer (TNBC) is the most heterogeneous and aggressive subtype of breast cancer, immunotherapy is emerging as a promising therapy.
Kexin Deng, Juping Sun, Junyu Liu, Yuqi Zhang, Wanwan Liu, Xiaobin Li, Han Wu, Juan Li, Jisong Zhang, Chanyuan Jin, Can Yang Zhang   +10 more
wiley   +1 more source

Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma. [PDF]

World J Gastroenterol
Watanabe T.
europepmc   +1 more source

Interferon regulatory factor 1 protects against chikungunya virus-induced immunopathology by restricting infection in muscle cells [PDF]

, 2017
Diamond, Michael S, Nair, Sharmila, Poddar, Subhajit, Shimak, Raeann M   +3 more
core   +2 more sources